Enclomiphene for Anovulatory Infertility Treatment
Primary Indication and Effectiveness
- The American Academy of Family Physicians recommends clomiphene citrate as the first-line treatment for ovulation induction in anovulatory infertility, due to its well-established safety and efficacy 1
- Clomiphene citrate is the treatment of first choice for normally estrogenized, anovulatory women (WHO group II anovulation), which includes conditions like polycystic ovary syndrome (PCOS) 1
- Approximately 80% of women with pure anovulatory infertility will ovulate with clomiphene treatment, and about 50% of those who ovulate will conceive 1
- Alternative or adjunctive approaches, such as low-dose gonadotropin therapy, are recommended if clomiphene fails after appropriate trials, to induce monofollicular development with lower hyperstimulation risk 1
- Weight loss of as little as 5% of initial body weight improves metabolic and reproductive abnormalities in PCOS and is associated with improved ovulation and pregnancy rates, as recommended by the American Academy of Family Physicians 1
Critical Safety Considerations and Monitoring
- Clomiphene is contraindicated in patients with liver disease, especially decompensated cirrhosis, and should only be used when sufficient endogenous estrogen levels are present (not in hypogonadotropic hypogonadism) 2
- Ovarian hyperstimulation syndrome is a potential complication, especially with multifollicular development, and clomiphene can alter serum lipid profiles 2